Episode Details
Back to Episodes
Gedatolisib Shows Promise in Breast Cancer Trial
Description
Celcuitys phase three VICTORIA-one trial for gedatolisib showed positive top-line results, outperforming alpelisib in second-line treatment for HR-positive, HER two-negative advanced breast cancer. The drug, combined with fulvestrant and palbociclib, demonstrated strong stats and good safety. Celcuity is expanding VICTORIA-two into first-line for endocrine-sensitive patients and plans to present full details at ASCO on June second. The company is also working on a sub-Q version of gedatolisib and has a commercial team ready to target a five billion dollar market.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/096206568d7f44bd